Wockhardt jumped over 3% after exiting its US generics business and gaining USFDA nod for 2 injectables. Analyst Vijay Gupta flagged a strong breakout, with support at ₹1,749 and resistance near ₹1,940. Rising OBV and improved fundamentals add momentum. With buzz around monetising its hospital unit, Gupta says ₹2,000+ is possible if earnings upgrades support the move.